Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 6.5% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care, Inc. ($TNDM) specializes in diabetes management solutions, particularly known for its automated insulin delivery systems. The company has expanded its Mobi insulin pump to include compatibility with Android smartphones, in addition to its existing iPhone support.

Why is Tandem Diabetes Care, Inc. going up?

TNDM stock is up 6.5% on Mar 11, 2026 13:43

• The bullish movement in TNDM stock today is due to the positive market reception of the company's expansion of the Mobi automated insulin delivery system to Android users. This move has significantly widened the potential user base for Tandem's technology, reflecting a strategic decision to tap into a larger market segment.
• Vanguard Group Inc.'s decision to trim its position in TNDM by 4.2% may have initially raised concerns among investors. However, the market sentiment was likely buoyed by the company's better-than-expected earnings report for the latest quarter, showcasing strong financial performance despite remaining unprofitable.
• The increased analyst attention, with Truist Securities raising its price target and Lake Street Capital Markets upgrading the stock to a Buy rating, also contributed to the positive momentum in TNDM stock, indicating growing confidence in the company's growth prospects and technological advancements in the diabetes management sector.
• Overall, Tandem Diabetes Care's strategic expansion into the Android market, coupled with favorable analyst ratings and robust financial performance, has fueled investor optimism and driven the bullish movement in the stock today.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Tandem Diabetes Care, Inc. $TNDM Position Trimmed by Vanguard Group Inc.

Vanguard Group Inc. reduced its stake in Tandem Diabetes Care (TNDM) by 4.2% in the third quarter, selling 306,516 shares but still holding a significant 10.45% stake valued at $85.75 million. Despite analysts having a mixed "Hold" consensus with an average target price of $28.11, the company reported better-than-expected earnings for the latest quarter though it remains unprofitable. Other institutional investors showed varied activity, with some increasing and others acquiring new positions in TNDM.

https://www.marketbeat.com/instant-alerts/filing-tandem-diabetes-care-inc-tndm-position-trimmed-by-vanguard-group-inc-2026-03-06/

Tandem Diabetes expands Mobi Insulin Pump to Android users

Tandem Diabetes Care Inc. has expanded its Mobi automated insulin delivery system to include compatibility with Android smartphones, making it accessible to a wider range of users beyond the initial iPhone-only launch. The FDA-cleared technology, powered by Control-IQ+, is available on select Google Pixel and Samsung Galaxy models, offering users improved time-in-range for glucose levels and a compact, discreet pump design. This move reflects a broader industry trend toward smartphone-controlled, miniaturized, and highly effective automated insulin delivery systems.

https://www.medicaleconomics.com/view/tandem-diabetes-expands-mobi-insulin-pump-to-android-users

Tandem Diabetes adds Android support for Mobi insulin pump

Tandem Diabetes Care, Inc. has expanded its Mobi automated insulin delivery system to include compatibility with Android smartphones in the U.S., through the Tandem Mobi mobile app. This move broadens the accessibility of their Control-IQ+ technology, previously available only on iPhones, to a larger user base. The company recently increased its convertible senior notes offering to $265 million and has seen positive analyst attention, with Truist Securities raising its price target and Lake Street Capital Markets upgrading the stock to a Buy rating.

https://www.investing.com/news/company-news/tandem-diabetes-adds-android-support-for-mobi-insulin-pump-93CH-4542437

Tandem Mobi Now Compatible with Android Smartphones

Tandem Diabetes Care has announced that its Tandem Mobi automated insulin delivery system is now compatible with Android smartphones in the U.S. This expansion allows more users to manage their diabetes directly from their Android devices, following its initial launch with iPhones in 2024. The system, recognized for its small size and driven by Control-IQ+ technology, aims to enhance convenience and accessibility for individuals with diabetes.

https://www.businesswire.com/news/home/20260304073769/en/Tandem-Mobi-Now-Compatible-with-Android-Smartphones

Tandem Mobi Now Compatible with Android Smartphones

Tandem Diabetes Care, Inc. has announced that its Tandem Mobi insulin delivery system is now compatible with Android smartphones in the U.S. This expansion allows more users to manage their diabetes directly from their personal devices, enhancing convenience and flexibility. The Mobi system, powered by Control-IQ technology, aims to broaden access to advanced diabetes management for a wider population.

https://www.eagletribune.com/region/tandem-mobi-now-compatible-with-android-smartphones/article_fde49c25-203d-5006-abf0-285d45536079.html

Trending Today

McCormick & Company Incorporated ($MKC) Stock Forecast: Down 5.7% Today

Macy's Inc ($M) Stock Forecast: Down 5.0% Today

Credo Technology Group ($CRDO) Stock Forecast: Up 5.8% Today

Chegg Inc. ($CHGG) Stock Forecast: Down 5.1% Today

Hims & Hers Health Inc. ($HIMS) Stock Forecast: Up 5.9% Today

ConAgra Brands Inc. ($CAG) Stock Forecast: Down 5.8% Today

Okta Inc. ($OKTA) Stock Forecast: Up 5.9% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Up 6.1% Today

Moderna Inc. ($MRNA) Stock Forecast: Up 5.6% Today

Intel Corporation ($INTC) Stock Forecast: Up 5.5% Today

Tandem Diabetes Care, Inc. Price History

24.01.2026 - TNDM Stock was up 5.3%

• Tandem Diabetes Care's bullish movement today could be attributed to the positive market reception of its proposed private placement of convertible notes, signaling investor confidence in the company's growth prospects.
• The upgrade of Tandem Diabetes Care's stock rating by Lake Street Capital Markets, driven by the successful transition to a pharmacy distribution model, likely contributed to the bullish sentiment surrounding the company.
• The projected significant growth of the global insulin delivery devices market, with insulin pumps expected to dominate the market share, could have also positively influenced Tandem Diabetes Care's stock performance as a key player in this industry.
• Overall, the combination of strategic financial moves, positive analyst outlook, and favorable market trends in the healthcare sector likely fueled Tandem Diabetes Care's strong bullish movement today.

10.02.2026 - TNDM Stock was up 6.2%

• Tandem Diabetes Care's positive momentum is due to the launch of the Mobi insulin pump for Android users, expanding accessibility and convenience.
• The company's strategic move to make its Control-IQ+ technology compatible with a broader range of devices aligns with the industry's shift toward smartphone-operated automated insulin delivery systems.
• Favorable analyst attention, such as a price target increase and stock rating upgrade, has bolstered investor confidence in Tandem Diabetes Care's growth potential.
• With the recent completion of a $265 million convertible bond offering, the company's funding and valuation landscape has been reshaped, offering flexibility for future growth but also raising concerns about potential share dilution. It is advisable for investors to monitor the company's utilization of these funds in comparison to its current financial performance.

20.01.2026 - TNDM Stock was up 31.3%

• Adjusting Tandem Diabetes Care's price target upwards and maintaining a Hold rating likely contributed to investor optimism and buying interest in the stock.
• Tandem Diabetes Care's record-setting Q4 and full-year 2025 financial performance, surpassing $1 billion in sales, and achieving double-digit growth with improved profitability, showcased the company's strong fundamentals and growth potential.
• The strategic shift towards a "pay-as-you-go" reimbursement structure in the U.S. pharmacy channel, despite near-term revenue headwinds, signals a long-term focus on market expansion and profitability, which could have positively influenced investor sentiment.
• The introduction of new technologies like Control-IQ+ and Mobi Tubeless, along with strong financial results and optimistic 2026 guidance, likely fueled investor confidence and contributed to the significant bullish movement in Tandem Diabetes Care's stock price.

23.01.2026 - TNDM Stock was up 10.1%

• Tandem Diabetes Care's stock witnessed a surge of over 32% due to record margins and a revenue beat, supported by strong demand for its insulin pumps and enhanced gross margin.
• An upgrade by Lake Street Capital Markets to a Buy rating with a price target of $50.00 bolstered investor confidence, underscoring the company's successful shift to a pharmacy distribution model.
• The projected growth of the global insulin delivery devices market, particularly in insulin pumps leading the market share, also contributed to positive sentiment surrounding Tandem Diabetes Care.
• A combination of robust financial performance, margin expansion, and positive sales forecasts for 2026 resulted in a short squeeze and a notable increase in Tandem Diabetes Care's stock price.

23.01.2026 - TNDM Stock was up 6.3%

• Tandem Diabetes Care (TNDM) saw a remarkable 33% surge in its stock performance today, propelled by exceptional margins and outperforming revenue figures, prompting a short squeeze and a notable price upswing.
• The company delivered robust results in the fourth quarter, driven by a strong demand for its insulin pumps and an enhanced gross margin, contributing to the significant rise in its stock value.
• With an innovative pay-as-you-go pharmacy model that is augmenting margin expansion and generating recurring revenue, Tandem Diabetes Care is well-positioned for sustained profitable growth in 2026, with anticipated sales ranging between $1.065 billion and $1.085 billion.
• Tandem Diabetes Care's strategic initiatives for future expansion, such as the emphasis on the "pay-as-you-go" approach and the projected increase in pump shipments for 2026, have elicited positive responses from investors and analysts, despite a slightly lower-than-expected sales forecast for the fiscal year 2026.

20.01.2026 - TNDM Stock was up 39.4%

• Following the release of its Q4 2025 earnings report, Tandem Diabetes Care (TNDM) saw a strong bullish movement, with record-setting sales surpassing $1 billion and double-digit growth.
• Positive market response was observed towards TNDM's enhanced profitability, operational improvements, and the launch of new technologies like Control-IQ+ and Mobi Tubeless, reflecting investor confidence in the company's strategic direction.
• Despite issuing cautious sales guidance for 2026 due to transitional challenges from new business models, investors displayed optimism in TNDM's potential long-term profitability, leading to a rise in the stock price during after-hours trading.
• TNDM's ability to surpass revenue projections, enhance operating margins, and anticipate ongoing sales growth, particularly with the introduction of new pay-as-you-go pharmacy structures, contributed to the optimistic sentiment surrounding the stock.

25.01.2026 - TNDM Stock was down 7.8%

• The disclosure of pricing and upsizing details of the private placement of convertible senior notes due in 2032 likely sparked investor worries about possible share dilution, contributing to the prevailing bearish sentiment.
• Despite the favorable development of a stock rating upgrade by Lake Street Capital Markets attributed to a successful transition to a pharmacy distribution model, the attention on the convertible notes offering appeared to overshadow the favorable shift in the company's business approach.
• Investors are possibly exercising caution regarding the company's intention to utilize the proceeds for potential acquisitions, raising uncertainties about future growth and profitability.
• Market response suggests that while the strategic shift's long-term advantages are acknowledged, immediate concerns regarding share dilution and capital deployment choices are exerting a negative influence on the stock's performance.

27.01.2026 - TNDM Stock was down 5.1%

• Reduction of stake by Envestnet Asset Management Inc. by 15% could have signaled lack of confidence in the company's future prospects, contributing to the bearish movement.
• Despite beating quarterly EPS and revenue estimates, the fact that Tandem Diabetes Care remains unprofitable might have raised concerns among investors, leading to the downward trend in the stock price.
• The pricing of an upsized private placement of convertible senior notes due 2032 could have diluted the value of existing shares, impacting the stock negatively.
• Mixed signals from analysts, with a "Hold" rating and a consensus target price of $28.00, might have added uncertainty to investors, influencing the bearish movement in the stock.

06.02.2026 - TNDM Stock was down 5.2%

• The expansion of Tandem's Mobi automated insulin delivery system to Android smartphones, while a positive development for accessibility and user convenience, may have raised concerns about potential competition in the market, leading to a bearish sentiment among investors.
• Despite receiving rating upgrades and achieving over $1 billion in worldwide sales, the market may have reacted negatively to the stock due to profit-taking by investors who were anticipating a bullish run following these positive developments.
• The announcement of further innovations planned for 2026, including a tubeless Mobi pump and an advanced insulin algorithm, could have created uncertainty among investors about the company's ability to maintain its current growth trajectory, contributing to the bearish movement in the stock price.

11.02.2026 - TNDM Stock was up 6.5%

• The bullish movement in TNDM stock today is due to the positive market reception of the company's expansion of the Mobi automated insulin delivery system to Android users. This move has significantly widened the potential user base for Tandem's technology, reflecting a strategic decision to tap into a larger market segment.
• Vanguard Group Inc.'s decision to trim its position in TNDM by 4.2% may have initially raised concerns among investors. However, the market sentiment was likely buoyed by the company's better-than-expected earnings report for the latest quarter, showcasing strong financial performance despite remaining unprofitable.
• The increased analyst attention, with Truist Securities raising its price target and Lake Street Capital Markets upgrading the stock to a Buy rating, also contributed to the positive momentum in TNDM stock, indicating growing confidence in the company's growth prospects and technological advancements in the diabetes management sector.
• Overall, Tandem Diabetes Care's strategic expansion into the Android market, coupled with favorable analyst ratings and robust financial performance, has fueled investor optimism and driven the bullish movement in the stock today.

05.02.2026 - TNDM Stock was down 5.4%

• The introduction of Tandem Mobi's compatibility with Android smartphones, potentially broadening its user base, could have prompted concerns about technical issues or integration challenges, leading to uncertainty among investors and selling pressure on the stock.
• Despite receiving favorable analyst upgrades and surpassing $1 billion in worldwide sales, doubts voiced in the healthcare sector may have influenced market sentiment toward Tandem Diabetes Care, contributing to its recent stock decline.
• Anticipation surrounding the company's upcoming innovations in 2026, such as a tubeless Mobi pump and an enhanced insulin algorithm, may have raised expectations while also introducing uncertainty about execution and market reception, resulting in a negative impact on the stock price.
• When considering the expanded market reach, positive ratings, financial achievements, and industry doubts, the collective effect might have created varying investor sentiments, ultimately leading to the recent decline in TNDM stock value.

03.02.2026 - TNDM Stock was down 5.7%

• A decline in TNDM stock value is likely due to investors selling their shares to lock in profits following a period of positive updates and price increases.
• Despite achieving over $1 billion in worldwide sales and receiving analyst rating upgrades, concerns of future financial obligations arose when the company issued $300 million in zero-coupon convertible notes due 2032, potentially leading to stock pullback.
• Mixed financial results, including a reported net loss for the half-year and challenges related to a high debt-equity ratio, may have further fueled the negative investor sentiment surrounding TNDM stock.